PubMed:30994353 / 81-279 JSONTXT

{"project":"sentences","denotations":[{"id":"TextSentencer_T2","span":{"begin":0,"end":198},"obj":"Sentence"},{"id":"T2","span":{"begin":0,"end":198},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Oncogenic BRAF mutations contribute to the development of a number of cancers, and small-molecule BRAF inhibitors have been approved by the Food and Drug Administration (FDA) for anticancer therapy."}

{"project":"pubmed-enju-pas","denotations":[{"id":"EnjuParser_T11","span":{"begin":0,"end":9},"obj":"JJ"},{"id":"EnjuParser_T12","span":{"begin":10,"end":14},"obj":"NN"},{"id":"EnjuParser_T13","span":{"begin":15,"end":24},"obj":"NNS"},{"id":"EnjuParser_T14","span":{"begin":25,"end":35},"obj":"VBP"},{"id":"EnjuParser_T15","span":{"begin":36,"end":38},"obj":"TO"},{"id":"EnjuParser_T16","span":{"begin":39,"end":42},"obj":"DT"},{"id":"EnjuParser_T17","span":{"begin":43,"end":54},"obj":"NN"},{"id":"EnjuParser_T18","span":{"begin":55,"end":57},"obj":"IN"},{"id":"EnjuParser_T19","span":{"begin":58,"end":59},"obj":"DT"},{"id":"EnjuParser_T20","span":{"begin":60,"end":66},"obj":"NN"},{"id":"EnjuParser_T21","span":{"begin":67,"end":69},"obj":"IN"},{"id":"EnjuParser_T22","span":{"begin":70,"end":77},"obj":"NNS"},{"id":"EnjuParser_T23","span":{"begin":77,"end":78},"obj":"-COMMA-"},{"id":"EnjuParser_T24","span":{"begin":79,"end":82},"obj":"CC"},{"id":"EnjuParser_T25","span":{"begin":83,"end":97},"obj":"JJ"},{"id":"EnjuParser_T26","span":{"begin":98,"end":102},"obj":"NN"},{"id":"EnjuParser_T27","span":{"begin":103,"end":113},"obj":"NNS"},{"id":"EnjuParser_T28","span":{"begin":114,"end":118},"obj":"VBP"},{"id":"EnjuParser_T29","span":{"begin":119,"end":123},"obj":"VBN"},{"id":"EnjuParser_T30","span":{"begin":124,"end":132},"obj":"VBN"},{"id":"EnjuParser_T31","span":{"begin":133,"end":135},"obj":"IN"},{"id":"EnjuParser_T32","span":{"begin":136,"end":139},"obj":"DT"},{"id":"EnjuParser_T33","span":{"begin":140,"end":144},"obj":"NNP"},{"id":"EnjuParser_T34","span":{"begin":145,"end":148},"obj":"CC"},{"id":"EnjuParser_T35","span":{"begin":149,"end":153},"obj":"NNP"},{"id":"EnjuParser_T36","span":{"begin":154,"end":168},"obj":"NNP"},{"id":"EnjuParser_T37","span":{"begin":169,"end":170},"obj":"-LRB-"},{"id":"EnjuParser_T38","span":{"begin":170,"end":173},"obj":"NNP"},{"id":"EnjuParser_T39","span":{"begin":173,"end":174},"obj":"-RRB-"},{"id":"EnjuParser_T40","span":{"begin":175,"end":178},"obj":"IN"},{"id":"EnjuParser_T41","span":{"begin":179,"end":189},"obj":"JJ"},{"id":"EnjuParser_T42","span":{"begin":190,"end":197},"obj":"NN"}],"relations":[{"id":"EnjuParser_R10","pred":"arg1Of","subj":"EnjuParser_T13","obj":"EnjuParser_T11"},{"id":"EnjuParser_R11","pred":"arg1Of","subj":"EnjuParser_T13","obj":"EnjuParser_T12"},{"id":"EnjuParser_R12","pred":"arg1Of","subj":"EnjuParser_T13","obj":"EnjuParser_T14"},{"id":"EnjuParser_R13","pred":"arg1Of","subj":"EnjuParser_T14","obj":"EnjuParser_T15"},{"id":"EnjuParser_R14","pred":"arg2Of","subj":"EnjuParser_T17","obj":"EnjuParser_T15"},{"id":"EnjuParser_R15","pred":"arg1Of","subj":"EnjuParser_T17","obj":"EnjuParser_T16"},{"id":"EnjuParser_R16","pred":"arg1Of","subj":"EnjuParser_T17","obj":"EnjuParser_T18"},{"id":"EnjuParser_R17","pred":"arg2Of","subj":"EnjuParser_T20","obj":"EnjuParser_T18"},{"id":"EnjuParser_R18","pred":"arg1Of","subj":"EnjuParser_T20","obj":"EnjuParser_T19"},{"id":"EnjuParser_R19","pred":"arg1Of","subj":"EnjuParser_T20","obj":"EnjuParser_T21"},{"id":"EnjuParser_R20","pred":"arg2Of","subj":"EnjuParser_T22","obj":"EnjuParser_T21"},{"id":"EnjuParser_R21","pred":"arg1Of","subj":"EnjuParser_T24","obj":"EnjuParser_T23"},{"id":"EnjuParser_R22","pred":"arg1Of","subj":"EnjuParser_T14","obj":"EnjuParser_T24"},{"id":"EnjuParser_R23","pred":"arg2Of","subj":"EnjuParser_T30","obj":"EnjuParser_T24"},{"id":"EnjuParser_R24","pred":"arg1Of","subj":"EnjuParser_T27","obj":"EnjuParser_T25"},{"id":"EnjuParser_R25","pred":"arg1Of","subj":"EnjuParser_T27","obj":"EnjuParser_T26"},{"id":"EnjuParser_R26","pred":"arg1Of","subj":"EnjuParser_T27","obj":"EnjuParser_T28"},{"id":"EnjuParser_R27","pred":"arg2Of","subj":"EnjuParser_T30","obj":"EnjuParser_T28"},{"id":"EnjuParser_R28","pred":"arg1Of","subj":"EnjuParser_T27","obj":"EnjuParser_T29"},{"id":"EnjuParser_R29","pred":"arg2Of","subj":"EnjuParser_T30","obj":"EnjuParser_T29"},{"id":"EnjuParser_R30","pred":"arg1Of","subj":"EnjuParser_T34","obj":"EnjuParser_T30"},{"id":"EnjuParser_R31","pred":"arg2Of","subj":"EnjuParser_T27","obj":"EnjuParser_T30"},{"id":"EnjuParser_R32","pred":"arg2Of","subj":"EnjuParser_T34","obj":"EnjuParser_T31"},{"id":"EnjuParser_R33","pred":"arg1Of","subj":"EnjuParser_T34","obj":"EnjuParser_T32"},{"id":"EnjuParser_R34","pred":"arg1Of","subj":"EnjuParser_T33","obj":"EnjuParser_T34"},{"id":"EnjuParser_R35","pred":"arg2Of","subj":"EnjuParser_T36","obj":"EnjuParser_T34"},{"id":"EnjuParser_R36","pred":"arg1Of","subj":"EnjuParser_T36","obj":"EnjuParser_T35"},{"id":"EnjuParser_R37","pred":"arg1Of","subj":"EnjuParser_T34","obj":"EnjuParser_T37"},{"id":"EnjuParser_R38","pred":"arg2Of","subj":"EnjuParser_T38","obj":"EnjuParser_T37"},{"id":"EnjuParser_R39","pred":"arg3Of","subj":"EnjuParser_T39","obj":"EnjuParser_T37"},{"id":"EnjuParser_R40","pred":"arg1Of","subj":"EnjuParser_T34","obj":"EnjuParser_T40"},{"id":"EnjuParser_R41","pred":"arg2Of","subj":"EnjuParser_T42","obj":"EnjuParser_T40"},{"id":"EnjuParser_R42","pred":"arg1Of","subj":"EnjuParser_T42","obj":"EnjuParser_T41"}],"namespaces":[{"prefix":"_base","uri":"http://kmcs.nii.ac.jp/enju/"}],"text":"Oncogenic BRAF mutations contribute to the development of a number of cancers, and small-molecule BRAF inhibitors have been approved by the Food and Drug Administration (FDA) for anticancer therapy."}